Predictors of Response to Augmentation With Ziprasidone (Geodon®) in Major Depressive Disorder
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The primary outcome of this study is to determine if predictors of response can select a population of patients with MDD that is effectively treatable by augmentation with ziprasidone.
Major depressive disorder (MDD) is a broad category, including many forms of depressive illness, including those with only a single major depressive episode, those with episodic recurrence with intervening well states, those with chronic depressive/anxious states without intervening euthymia, and those with manic symptoms that do not meet threshold definitions of full mania/hypomania.
In this heterogenous, large diagnostic definition, important groups of patients do not appear to respond well to antidepressants, and, conversely, based on observational studies, may respond well to neuroleptics. These predictors of response have begun to be identified and may serve to better design studies of neuroleptics in depressive illnesses.
Among these predictors of response in MDD are clinical features that are more similar to bipolar illness than unipolar depression. These include a family history of bipolar disorder, antidepressant-induced mania, highly recurrent depressive episodes (>5), atypical depression, early age of onset of depression (< age 20), failure to respond to antidepressants, and antidepressant tolerance (initial response followed by later loss of response).
The investigators propose to use these predictors to pick out patients that are more likely to respond to Geodon for MDD. This will be the first RCT of these predictors of depressive response applied to neuroleptics.
| Condition | Intervention | Phase |
|---|---|---|
|
Depression Bipolar Disorder |
Drug: ziprasidone Drug: Sugar pill |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Crossover Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Treatment |
| Official Title: | Predictors of Response to Augmentation With Ziprasidone (Geodon®) in Major Depressive Disorder : A 13-week, Double-Blind, Placebo-Controlled, Cross-Over Trial |
- The primary outcome of this study is to determine if predictors of response can select a population of patients with MDD that is effectively treatable by augmentation with ziprasidone. [ Time Frame: 6 weeks and 13 weeks ] [ Designated as safety issue: No ]
| Enrollment: | 64 |
| Study Start Date: | February 2010 |
| Study Completion Date: | December 2011 |
| Primary Completion Date: | December 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Placebo Comparator: Sugar Pill |
Drug: Sugar pill
The once-daily total daily dose will be 80-160 mg/d of the sugar pill. Dosing will begin at 20 mg BID with an escalation strategy based on target symptoms and tolerability, with a target dose range of 80-160 mg/d. Dose escalations will occur by increments of 20-40 mg weekly.
Other Name: Placebo
|
| Active Comparator: Ziprasidone |
Drug: ziprasidone
Ziprasidone will be administered as a pill. The once-daily total daily dose will be 80-160 mg/d of ziprasidone. Dosing will begin at 20 mg BID with an escalation strategy based on target symptoms and tolerability, with a target dose range of 80-160 mg/d. Dose escalations will occur by increments of 20-40 mg weekly.
Other Name: Geodon
|
Detailed Description:
This will be a three-site, block randomized (1:1 ratio) double-blind, placebo-controlled prospective cross-over study with 50 subjects. Patients will be randomized to receiving ziprasidone-washout-placebo or placebo- washout-ziprasidone for 13-weeks.
Primary and Secondary and safety outcomes: The primary outcome measure will be change from baseline Montgomery-Asberg Depression Rating Scale (MADRS) score to end of treatment; the secondary efficacy measure will be changes in other efficacy ratings (HAM-A, and CGI) along with changes in scales to measure functional improvement and quality of life (GAF). Safety outcomes will be determined by the BAS and SAS ratings and spontaneously reported adverse events on the case report form.
Eligibility| Ages Eligible for Study: | 18 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age 18-70 years.
- If female, nonpregnant/nonlactating
- If a sexually active female of reproductive potential, must be using adequate contraception (i.e., oral contraceptives, barrier protection, or prior tubal ligation)
- Currently meets DSM-IV criteria for a major depressive episode, non-psychotic.
- Having at least 3 of the following criteria listed for predictors of depressive response to neuroleptics: a family history of bipolar disorder, antidepressant-induced mania, highly recurrent depressive episodes (>5), atypical depression, early age of onset of depression (< age 20), failure to respond to antidepressants, and antidepressant tolerance (initial response followed by later loss of response). Inadequate response to antidepressants is identified as follows: having a score of ≥14 on the 17-item HAMD or a CGI-S score of ≥ 3 after a retrospective confirmation of an adequate trial of a single antidepressant (defined as a ≥ 6-week trial of acceptable therapeutic dose [≥ 40 mg of fluoxetine, paroxetine or citalopram, 20 mg of escitalopram, 60 mg of duloxetine, 37.5 mg of paroxetine CR, 150 mg of sertraline, 100 mg of fluvoxamine, 225 mg of venlafaxine XR, 30 mg of mirtazapine, 300 mg of bupropion, 75 mg of nortriptyline, 20 mg of protriptyline, 100 mg of amitriptyline or imipramine)
Exclusion Criteria:
- Bipolar depression
- Sensitivity to or failure to respond to ziprasidone by history or ziprasidone use in previous 3 months
- Active substance abuse or dependence in the previous 3 month
- Psychotic disorders
- Serious suicidality as evidenced by score of 3 or greater on suicide item of MADRS
- Medically unstable as judged by study investigators
- Lack of capacity to provide informed, written, consent to investigators
- Previous diagnosed cardiac arrhythmias
Contacts and Locations| United States, Massachusetts | |
| Tufts Medical Center | |
| Boston, Massachusetts, United States, 02111 | |
| United States, North Carolina | |
| Duke University School of Medicine | |
| Durham, North Carolina, United States, 27705 | |
| United States, South Carolina | |
| University of South Carolina | |
| Columbia, South Carolina, United States, 29203 | |
| Principal Investigator: | Nassir Ghaemi, MD MPH | Tufts Medical Center |
| Principal Investigator: | Ashwin Patkar, MD | Duke |
| Principal Investigator: | Meera Narasimhan, MD | University of South Carolina |
| Principal Investigator: | Prakash Masand, MD | Duke |
More Information
No publications provided
| Responsible Party: | Tufts Medical Center |
| ClinicalTrials.gov Identifier: | NCT01168674 History of Changes |
| Other Study ID Numbers: | 9238 |
| Study First Received: | July 21, 2010 |
| Last Updated: | January 14, 2013 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Tufts Medical Center:
|
Major Depressive Disorder MDD Bipolar Disorder |
BD Depression Major Depressive Disorder with Bipolar features |
Additional relevant MeSH terms:
|
Bipolar Disorder Depression Depressive Disorder Depressive Disorder, Major Affective Disorders, Psychotic Mood Disorders Mental Disorders Behavioral Symptoms Ziprasidone Serotonin Antagonists Serotonin Agents Neurotransmitter Agents |
Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Physiological Effects of Drugs Antipsychotic Agents Tranquilizing Agents Central Nervous System Depressants Central Nervous System Agents Therapeutic Uses Psychotropic Drugs Dopamine Antagonists Dopamine Agents |
ClinicalTrials.gov processed this record on May 16, 2013